- For those looking for the catalyst behind the double-digit decline in shares of TG Therapeutics (TGTX -14.5%), don't ask the company.
- "While [we] do not typically comment on unusual market activity [we are] not aware of any developments that would merit such trading activity," TGTX says, before reiterating that the next milestones are the initiation of combo trials for TG-1101 and BTK and/or PI3K delta inhibitors, and the presentation of Phase 1 data for TGR-1202. (PR)
TG Therapeutics doesn't know why stock is down
Oct 28 2013, 14:15 ET